Chinese drug maker Akeso, whose new cancer drug has outperformed a leading Western peer in clinical studies, is being hailed ...
CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that the ...
Takeda is sharpening its oncology focus amid an R&D revamp. Sun Pharma will acquire Checkpoint Therapeutics and an ...
Keros Therapeutics' stock has plummeted over 70% due to safety issues in its phase 2 PAH study, halting all trial arms. Learn more about KROS stock here.
Takeda’s revamped R&D strategy means the drugmaker’s oncology leaders are prioritizing work in tumors across thoracic, ...
Y Intercept Hong Kong Ltd acquired a new stake in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA – Free Report) in the 4th ...
Researchers at the Hong Kong University of Science and Technology (HKUST) have developed the world’s first kilowatt-scale ...
Researchers at the Hong Kong University of Science and Technology (HKUST) have developed the world's first kilowatt-scale ...
Chinese University team reports encouraging results and is recruiting more patients to include in CAR-T clinical trial Retiree Li Chun underwent various treatments for lymphoma for nine years before a ...